428 related articles for article (PubMed ID: 37587305)
1. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O
Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
[TBL] [Abstract][Full Text] [Related]
2. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil: Custo-Efetividade do Onasemnogeno Abeparvoveque (AVXS-101) em Comparação ao Nusinersena e Risdiplam em Pacientes com Atrofia Muscular Espinhal Tipo 1 no Brasil.
Fernandes BD; D'Athayde Rodrigues F; Cardoso Cirilo HN; Borges SS; Krug BC; Probst LF; Zimmermann I
Value Health Reg Issues; 2024 Mar; 40():108-117. PubMed ID: 38181723
[TBL] [Abstract][Full Text] [Related]
4. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.
Bitetti I; Lanzara V; Margiotta G; Varone A
Gene Ther; 2023 Aug; 30(7-8):592-597. PubMed ID: 35606491
[TBL] [Abstract][Full Text] [Related]
5. Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study.
Zhuang W; Lu M; Wu Y; Chen Z; Wang M; Wang X; Guan S; Lin W
Clin Drug Investig; 2023 Dec; 43(12):949-962. PubMed ID: 37995087
[TBL] [Abstract][Full Text] [Related]
6. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1.
Bischof M; Lorenzi M; Lee J; Druyts E; Balijepalli C; Dabbous O
Curr Med Res Opin; 2021 Oct; 37(10):1719-1730. PubMed ID: 34236007
[TBL] [Abstract][Full Text] [Related]
7. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N
J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693
[No Abstract] [Full Text] [Related]
8. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
[TBL] [Abstract][Full Text] [Related]
9. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments.
Dangouloff T; Botty C; Beaudart C; Servais L; Hiligsmann M
Orphanet J Rare Dis; 2021 Jan; 16(1):47. PubMed ID: 33485382
[TBL] [Abstract][Full Text] [Related]
10. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data.
Erdos J; Wild C
Eur J Paediatr Neurol; 2022 Jul; 39():1-10. PubMed ID: 35533607
[TBL] [Abstract][Full Text] [Related]
11. Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with Risdiplam.
Tosi M; Catteruccia M; Cherchi C; Mizzoni I; D'Amico A
Acta Myol; 2022; 41(3):117-120. PubMed ID: 36349185
[TBL] [Abstract][Full Text] [Related]
12. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
Dean R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Wiesner T; Malone DC; Bischof M; Toro W; Dabbous O
J Mark Access Health Policy; 2021 Feb; 9(1):1889841. PubMed ID: 33708361
[No Abstract] [Full Text] [Related]
13. Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry.
Servais L; Day JW; De Vivo DC; Kirschner J; Mercuri E; Muntoni F; Proud CM; Shieh PB; Tizzano EF; Quijano-Roy S; Desguerre I; Saito K; Faulkner E; Benguerba KM; Raju D; LaMarca N; Sun R; Anderson FA; Finkel RS
J Neuromuscul Dis; 2024; 11(2):425-442. PubMed ID: 38250783
[TBL] [Abstract][Full Text] [Related]
14. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
[No Abstract] [Full Text] [Related]
15. Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up.
Funato M; Kino A; Iwata R; Yumioka M; Yamashita K; Urui C; Uno R; Kondo E; Morioka E; Ogawa Y; Kawamura A; Kusukawa T; Minatsu H
Brain Dev; 2024 Jan; 46(1):62-67. PubMed ID: 37657961
[TBL] [Abstract][Full Text] [Related]
16. Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis.
Fox D; To TM; Seetasith A; Patel AM; Iannaccone ST
Adv Ther; 2023 Mar; 40(3):903-919. PubMed ID: 36534265
[TBL] [Abstract][Full Text] [Related]
17. The Japan Registry for Adult Subjects of Spinal Muscular Atrophy (jREACT-SMA): Protocol for a Longitudinal Observational Study.
Sahashi K; Hashizume A; Kuwatsuka Y; Chinen M; Saotome-Nakamura A; Ando M; Katsuno M
JMIR Res Protoc; 2022 Dec; 11(12):e38878. PubMed ID: 36520510
[TBL] [Abstract][Full Text] [Related]
18. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany.
Hahn A; Günther R; Ludolph A; Schwartz O; Trollmann R; Weydt P; Weiler M; Neuland K; Schwaderer MS; Hagenacker T;
Orphanet J Rare Dis; 2022 Jul; 17(1):276. PubMed ID: 35854272
[TBL] [Abstract][Full Text] [Related]
19. Polysomnography findings in children with spinal muscular atrophy after onasemnogene-abeparvovec.
Leon-Astudillo C; Wagner M; Salabarria SM; Lammers J; Berthy J; Zingariello CD; Byrne BJ; Smith BK
Sleep Med; 2023 Jan; 101():234-237. PubMed ID: 36442421
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy.
Kokaliaris C; Evans R; Hawkins N; Mahajan A; Scott DA; Sutherland CS; Nam J; Sajeev G
Adv Ther; 2024 Jun; 41(6):2414-2434. PubMed ID: 38705943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]